North Sea Therapeutics raises US$40m in Series B
NorthSea Therapeutics BV has raised US$40m to provide proof-of-concept of its NASH drug icosabutate.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1379 entries already.
Entries by Thomas Gabrielczyk
Merck and 4SC collaborate in immunooncology
/in News/by Thomas Gabrielczyk4SC AG and Merck KgaA have signed a supply agreement to start clinical tests of Mercks checkpoint blocker avelumab plus 4SCs HDAC I blocker domatinostat.
Novo Holdings invest US$12m in AMR companies
/in News/by Thomas GabrielczykMutabilis and IBT Vaccines have successfully bagged US$12m from the Novo Holdings REPAIR Impact Fund.
Fighting sepsis mortality
/in News/by Thomas GabrielczykCritical care experts have presented data supporting the thesis that three specific pathways are the cause for about 90% of sepsis mortality.
Antabio SAS advances cystic fibrosis programme
/in News/by Thomas GabrielczykAntabio SAS has got a US-$4.4m tranche from CARB-X to advance preclinical development of its P. aeruginosa treatment in Cystic Fibrosis patients
Hydrogel fights wound infection and inflammation
/in News/by Thomas GabrielczykSwedish and Danish researchers have created a hydrogel that kills various types of bacteria and reduces inflammation in mice and pigs with infected wounds.
Merry Christmas and a Happy New Year
/in News/by Thomas GabrielczykEuropean Biotechnology Magazine will be back with breaking news and backgrounds on 2 January. Best wishes
British diagnostics play OBD lands contract with US pharma
/in News/by Thomas GabrielczykThe technology of Oxford-based Oxford Biodynamics (OBD) promises insights into why immunotherapies only work in some patients but not in all. A major US pharma company now wants to validate […]
Truffle’s BioMedTech fund filled with 250m
/in News/by Thomas GabrielczykParis-based European venture capital company Truffle Capital closed its 250m BioMedTech fund celebrating its company building approach.
Biomarker identifies residual congestion in heart failure patients
/in News/by Thomas GabrielczykData from 1,200 heart failure patients demonstrate that high discharge levels of the biomarker bio-ADM® (bioactive Adrenomedullin) indicate residual congestion in heart failure patients.